Skip to main content
. 2022 Jun 23;41(1):43–53. doi: 10.1200/JCO.22.00205

FIG A1.

FIG A1.

OncoPrint of tumor gene mutations in the BAYOU study population. The OncoPrint illustrates the 20 most common gene mutations identified in tumors of patients enrolled in the BAYOU study. The two most common mutations were loss of p53 function (59.5%) and TERT promoter mutations (55.6%). A large number of tumors presented with defects in one or more genes involved chromatin remodeling: MLL2 (34%), KDM6A (25.5%), and ARID1A (12.4%), whereas mutations in the DNA damage repair genes ATM and BRCA2 were present in 8.5% and 4.6% of tumors, respectively. Loss of the cell cycle control genes CDKN2A and CDKN2B were identified in 32.7% and 28.1%, respectively; the adjacent MTAP gene was codeleted alongside both genes in 24.8% of tumors, suggesting loss of a significant region of chromosome 9. Common mutated driver genes were FGFR3 (20.3%), PIK3CA (19%), ERBB2 (12.4%), and KRAS/HRAS (11.1%), as previously described FGFR3 mutations were mutually exclusive with KRAS/HRAS mutations and with RB1, present in 13.7% of tumors. Trunc/FS, truncation/frameshift; VUS, variant of unknown significance.